Kawasaki disease is a systemic vasculitis that affects infants and young children 1-3. Kawasaki disease is now the leading cause of acquired heart disease among children in North America, Europe and Japan 4,5. The cardiovascular sequelae resulting from childhood Kawasaki disease are increasingly recognized to extend into adulthood, and the disease is no longer considered self-limiting 6-9. The triggering agents for Kawasaki disease remain unidentified; however, results from our laboratory 10,11 and others 12,13 are consistent with the interpretation that a conventional antigen is probably responsible. Coronary arteritis and predominantly coronary artery aneurysms (CAAs) occur in up to 30% of untreated children, although this rate is reduced to 5-7% in children treated with high-dose intravenous immunoglobulin (IVIG) 3,14,15. IVIG treatment leads to CAA regression in 60-75% of patients with Kawasaki disease 16,17. However, the exact mechanisms by which IVIG reduces the rate of cardiovascular complications are unknown 18. Up to 15-20% of patients with Kawasaki disease do not respond to IVIG treatment, and these individuals have an increased rate of CAA development 3,15,19-21. Kawasaki disease is associated with infiltration of the coronary artery wall by a broad variety of innate and adaptive immune cells. Immunohistochemical analysis of human post-mortem tissues shows accumulation in the arterial wall of monocytes, macrophages and neutrophils 22,23 , and the presence of activated CD8 + T cells 24 as well Aetiological agents The causative agents initiating the disease have still not been identified >50 years after the first description of Kawasaki disease. However, the trigger is suspected to be of viral origin and to enter the body through the